Stay updated on Switch to Dolutegravir + Rilpivirine Clinical Trial
Sign up to get notified when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.

Latest updates to the Switch to Dolutegravir + Rilpivirine Clinical Trial page
- CheckyesterdayChange DetectedAccess to the study record is now blocked by a 403 Forbidden error page, replacing the prior detailed study content and navigation. This reflects an access restriction rather than a data update to the study record.SummaryDifference20%

- Check8 days agoChange DetectedThe page footer now displays Revision: v3.7.0, replacing the previous v3.6.6. This reflects a version update to the page rather than a change to study content.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s revision tag was updated from v3.6.5 to v3.6.6, signaling a new release/patch rather than a content alteration. This appears to be a backend/format update rather than a change to study data or visible content.SummaryDifference0.0%

- Check29 days agoChange DetectedA new line '2014 ( U.S. NIH Grant/Contract )' was added to the study's identifiers. This reflects the NIH funding source for the trial.SummaryDifference0.0%

- Check43 days agoChange DetectedIPD sharing information and related metadata were added to the study page, including IPD access details and plan descriptions, along with updated revision metadata.SummaryDifference100%

- Check50 days agoChange DetectedIPD sharing information, study documents, and related metadata were removed from the Study Details page, reducing public access to data-sharing details and essential documentation.SummaryDifference19%

Stay in the know with updates to Switch to Dolutegravir + Rilpivirine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.